Project Name: Multiple Sclerosis (MS) Accelerating Patient Review for Improved Outcomes

Project Summary:

The CWP aims to foster collaboration between Novartis and the CW Partner to enhance the multiple sclerosis service delivery for patients with relapsing remitting multiple sclerosis (RRMS). Through this partnership, the parties  seek to leverage their combined expertise to improve patient outcomes and streamline healthcare processes. The ultimate goal is to develop innovative solutions that address the challenges faced by patients diagnosed with relapsing remitting multiple sclerosis, and provide more efficient, effective care.

The CWP aims to introduce a clinical fellow, band 8a, and administrative support, band 3, to the CW Partner’s MS service, optimise the CW Partner’s MS database to ensure all MS patient records are coded appropriately, track and monitor patients on disease modifying therapies, create a service protocol review and manage and monitor adherence to it.

Success of the CWP  will be measured by the following KPIs:

  • A reduction in the number of patients requiring a review by the MS Team, from a baseline of 1,400 patients.
  • A reduction in the number of patients on low efficacy DMTs not seen on a yearly basis by the MS Team, from a baseline of 756 patients.
  • The number of completed MS clinic audits (relapse clinic, new patients, low efficacy DMT patients) during the CWP.

By continuously monitoring these metrics, the CWP seeks to ensure tangible improvements in healthcare provision and patient well-being.

Milestones: 

Milestone 1: CWP kick-off meeting and set up of subsequent quarterly reviews.

Milestone 2: Recruitment and onboarding of the CWP roles, clinical fellow, band 8a, and administrative support, band 3, and clinic start. 

Milestone 3: Commencement of data analysis for baseline measures, and 3 month CWP review meeting. 

Milestones 4 to 6: clinical activity with data submission and CWP review every 3 months, with the submission of a business case for future funding of the CWP Roles post CWP.

Milestone 7: CWP wrap up meeting and outcomes summary finalised.

Expected Benefits: 

Patient.

  • Improved patient outcomes due to faster time from referral to treatment time.
  • For patients reviewed in clinics, access to NICE recommended therapy.
  • Enhanced patient experience and satisfaction of the NHS MS service by reducing unnecessary waiting times.

CW Partner (Ie: NHS).

  • Appropriate use of skill set across the service.
  • Accelerated access to services.
  • Improved quality of care.
  • Reduction in patient waiting lists.
  • Improved MDT efficiency and outcomes.
  • Improved experience of staff by spreading workload.

Novartis.

  • Novartis is likely to see positive outcomes as a result of the collaborative working project with the CW Partner. By enhancing the multiple sclerosis service delivery, the project aims to improve patient outcomes for those patients with relapsing remitting multiple sclerosis (RRMS). As more patients are reviewed, there is potential for greater utilization of Novartis's medicines, in line with national and local guidelines, where appropriate, leading to improved patient care.
  • Better understanding of the RRMS patient management pathway, improved understanding of the pressure points and priorities associated with the MS service. This will enable Novartis to build better projects in this therapy area in other regions of the UK.

Start Date & Duration: August 2025 for 27 months or CWP completion, whichever should first occur.

FA-11481804 | July 2025